JP7373151B2 - 新規化合物、および、その利用 - Google Patents

新規化合物、および、その利用 Download PDF

Info

Publication number
JP7373151B2
JP7373151B2 JP2020531344A JP2020531344A JP7373151B2 JP 7373151 B2 JP7373151 B2 JP 7373151B2 JP 2020531344 A JP2020531344 A JP 2020531344A JP 2020531344 A JP2020531344 A JP 2020531344A JP 7373151 B2 JP7373151 B2 JP 7373151B2
Authority
JP
Japan
Prior art keywords
compound
solution
mmol
trpv1 receptor
reaction vessel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020531344A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020017557A1 (ja
JPWO2020017557A5 (https=
Inventor
久志 土居
恭良 渡辺
宇貴秀 立石
大輔 加納
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Medical and Dental University NUC
RIKEN
Original Assignee
Tokyo Medical and Dental University NUC
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Medical and Dental University NUC, RIKEN filed Critical Tokyo Medical and Dental University NUC
Publication of JPWO2020017557A1 publication Critical patent/JPWO2020017557A1/ja
Publication of JPWO2020017557A5 publication Critical patent/JPWO2020017557A5/ja
Priority to JP2023177000A priority Critical patent/JP7679000B2/ja
Application granted granted Critical
Publication of JP7373151B2 publication Critical patent/JP7373151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/29—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Optics & Photonics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020531344A 2018-07-17 2019-07-17 新規化合物、および、その利用 Active JP7373151B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023177000A JP7679000B2 (ja) 2018-07-17 2023-10-12 新規化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018134457 2018-07-17
JP2018134457 2018-07-17
PCT/JP2019/028110 WO2020017557A1 (ja) 2018-07-17 2019-07-17 新規化合物、および、その利用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023177000A Division JP7679000B2 (ja) 2018-07-17 2023-10-12 新規化合物

Publications (3)

Publication Number Publication Date
JPWO2020017557A1 JPWO2020017557A1 (ja) 2021-08-05
JPWO2020017557A5 JPWO2020017557A5 (https=) 2022-08-15
JP7373151B2 true JP7373151B2 (ja) 2023-11-02

Family

ID=69164538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020531344A Active JP7373151B2 (ja) 2018-07-17 2019-07-17 新規化合物、および、その利用
JP2023177000A Active JP7679000B2 (ja) 2018-07-17 2023-10-12 新規化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023177000A Active JP7679000B2 (ja) 2018-07-17 2023-10-12 新規化合物

Country Status (2)

Country Link
JP (2) JP7373151B2 (https=)
WO (1) WO2020017557A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115057906B (zh) * 2022-07-28 2022-12-02 中节能万润股份有限公司 利用去氢表雄酮合成胆固醇的方法
KR102805959B1 (ko) * 2023-09-18 2025-05-12 현대제철 주식회사 빌렛 주편 절단 장치

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BONACORSI, Samuel J. Jr. et al.，Synthesis of multi-labeled [14C]aripiprazole，Journal of Labelled Compounds & Radiopharmaceuticals，2006年，vol.49, no.1，pp.1-9
VAN VEGHEL, Daisy et al.，New Transient Receptor Potential Vanilloid Subfamily Member 1 Positron Emission Tomography Radioligands: Synthesis, Radiolabeling, and Preclinical Evaluation，ACS Chemical Neuroscience，2013年，vol.4, no.4，pp.624-634
VAN VEGHEL, Daisy et al.，Synthesis and biological evaluation of [11C]SB366791: A new PET-radioligand for in vivo imaging of the TRPV1 receptor，Nuclear Medicine and Biology，2013年，vol.40, no.1，pp.141-147

Also Published As

Publication number Publication date
JP2023184564A (ja) 2023-12-28
WO2020017557A1 (ja) 2020-01-23
JPWO2020017557A1 (ja) 2021-08-05
JP7679000B2 (ja) 2025-05-19

Similar Documents

Publication Publication Date Title
JP7679000B2 (ja) 新規化合物
TW200307524A (en) Non-invasive diagnostic imaging technology for mitochondria dysfunction using radiolabeled lipophilic salts
TWI543769B (zh) 用於中樞神經系統或腫瘤疾病的成像、診斷及／或治療之化合物
JP2024056729A (ja) 放射線標識した前立腺特異的膜抗原（ＰＳＭＡ）阻害剤 ［１８Ｆ］ＤＣＦＰｙＬ の改良合成
BRPI0821241B1 (pt) Processo para a produção de um composto orgânico marcado com flúor radioativo
Brandau et al. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma
Rbah-Vidal et al. Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [18F] ICF01006, a highly promising melanoma PET tracer
US7731940B2 (en) Compositions and methods related to serotonin 5-HT1A receptors
Kanegawa et al. Synthesis and evaluation of radioiodinated (S, S)-2-(α-(2-iodophenoxy) benzyl) morpholine for imaging brain norepinephrine transporter
Zeng et al. Synthesis and evaluation of [18F]-fluoromethyl triphenylphosphonium cation as a novel mitochondria-specific positron emission tomography tracer
JP6609868B2 (ja) 放射性ハロゲン標識ピリド［１，２−ａ］ベンゾイミダゾール誘導体化合物
US9205156B2 (en) Molecular imaging agents
Kopka et al. 18F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases
US20160058895A1 (en) Radiolabeled gnrh antagonists as pet imaging agents
US20180064742A1 (en) Pet imaging tracer for imaging prostate cancer
KR20180083812A (ko) 악성 흑색종 진단용 방사성 화합물 및 그의 용도
JP7688339B2 (ja) 新規化合物、およびその利用
Cao et al. Synthesis and preliminary evaluation of 131I-9-iodovinyl-tetrabenazine targeting vesicular monoamine transporter 2
Passannante et al. Pharmacokinetic Evaluation of New Drugs Using a Multi-Labelling Approach and PET Imaging: Application to a Drug Can-didate with Potential Application in Neuromuscular Disorders. Biomedicines 2023, 11, 253
JP7438197B2 (ja) 多環式芳香族アミンの第四級アンモニウム塩の放射標識化合物、陽電子放射断層撮影の診断方法における放射標識化合物の使用、及び多環式芳香族アミンの第四級アンモニウム塩の放射標識化合物を含有する医薬組成物
US20130183239A1 (en) Isotopic carbon choline analogs
JP7024960B2 (ja) Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
Yang et al. Radiopharmaceuticals
JP2012207995A (ja) 脳内ノルエピネフリン・トランスポータを標的とする放射性臭素標識ｐｅｔ分子イメージングプローブ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220715

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231012

R150 Certificate of patent or registration of utility model

Ref document number: 7373151

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350